Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24124997 | 0.90 | ALDH1A1 (0.59) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL8192718 | 0.90 | ALDH1A1 (0.77) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL25922244 | 0.89 | PARP1 (0.71) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL30270577 | 0.89 | PARP1 (0.71) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL1466793 | 0.88 | GAA (0.75) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL25920730 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL24124625 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL14073692 | 0.86 | ALDH1A1 (0.72) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL24124197 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPTPOLBKMT2AGAA | |
| SCHEMBL14073031 | 0.84 | ALDH1A1 (0.69) | ALDH1A1MAPTPOLBKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | ALDH1A1 445/4885MAPT 2713/4885POLB 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.